Society of Gynecologic Oncology Annual Meeting on Women’s Cancer

The Society of Gynecologic Oncology Annual Meeting on Women’s Cancer Annual Meeting is hosted by Society of Gynecologic Oncology. The meeting offers educational and scientific sessions for those who treat and care for women with gynecologic cancer, including physicians and pharmacy professionals.

Next Steps Following Phase 2 Trial Assessing Niraparib in Treatment of Uterine Serous Carcinoma

March 22, 2022

Video

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses next steps following the results of the phase 2 trial assessing niraparib on the treatment of patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.

Clincial Trials Show Niraparib Improves PFS With Tolerable Safety Profile Following Response to Platinum-based Chemotherapy in Ovarian Cancer

March 22, 2022

Article

Niraparib shows promise in patients with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Implications of Phase 2 Trial Assessing Niraparib in the Treatment of Uterine Serous Carcinoma

March 21, 2022

Video

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses the implications of the phase 2 trial assessing niraparib on the treatment of patients with stage III, stage IV, or platinum-sensitive recurrent uterine serous carcinoma.

PARP Inhibitors Play Important Role in Frontline, Recurrent Maintenance Treatment of Ovarian Cancer

March 21, 2022

Article

Growing evidence indicates that PARP inhibition, both as frontline maintenance and recurrent maintenance, is important for many patients with ovarian cancer.

Endpoints of Phase 2 Trial Assessing Niraparib in Treatment of Uterine Serous Carcinoma

March 21, 2022

Video

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses the endpoints of the phase 2 trial assessing niraparib in patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.

Patient Population, Inclusion Requirements During Phase 2 Trial Assessing Niraparib for Uterine Serous Carcinoma Treatment

March 20, 2022

Video

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses how patients were selected for the phase 2 trial assessing niraparib in patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.

SGO President: Diversity of Oncology Practitioners ‘Allows Us to Address Barriers to Better Health Outcomes’ for Patients

March 20, 2022

Video

S. Diane Yamada, MD, president of the Society of Gynecologic Oncology (SGO), discusses how SGO shapes and guides the direction of medical researchers and health care professionals in the gynecologic oncology field.

Approaching Treatment of Newly Diagnosed or Recurrent Ovarian Cancer With PARP Inhibitors

March 20, 2022

Article

Only 40% of patients with platinum sensitive disease are receiving a PARP inhibitor in the first-line setting.

Assessing Therapeutic Approach to Treatment-Naïve Advanced Ovarian Cancer

March 20, 2022

Article

Data from the SOLO-1 trial highlight that even with an excellent prognostic group, patients with ovarian cancer still benefit from the use of a PARP inhibitor.

With New Options for the Treatment of Cervical Cancer, Considering Individual Patient Characteristics is Essential

March 20, 2022

Article

The death rate from cervical cancer has dropped by more than 50% since 1975.